This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of Daiichi Sankyo Europe GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. Daiichi Sankyo Europe GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
| . | Edoxaban | is | licensed | only | in | Japan | for | the | prevention | of | VTE | after | major | orthopaedic | surgery, | under | the | brand | name | Lixiana(R) | In | Europe, | edoxaban | has | not | been | approved | yet. | Daiichi | Sankyo | continues | to | develop | edoxaban | at | a | global | level | as | a | potential | new | treatment | for | stroke | prevention | in | atrial | fibrillation, | and | the | treatment | and | prevention | of | recurrent | VTE |
References
1) T. Fuji et al., Edoxaban Versus Enoxaparin for the Prevention of Venous
Thromboembolism: Pooled Analysis of Venous Thromboembolism and Bleeding from STARS
E-III and STARS J-V: The 53rd American Society of Hematology Annual Meeting and
Exposition, December 10-13, 2011.
2) T. Fuji et al., Edoxaban versus enoxaparin for thromboprophylaxis after total
knee replacement: The STARS E-III trial 21st International Congress of Thrombosis,
July 6 - 9 2010, Milano.
3) T. Fuji et al., Efficacy and Safety of Edoxaban Versus Enoxaparin for the
Prevention of Venous Thromboembolism Fol-lowing Total Hip Arthroplasty: STARS J-V
trial, American Society of Hemotology, December 4-7 2010, Orlando, Florida.
4) Deitelzweig S, Lin J, Johnson BH, Schulman KL. Prevalence of venous
thromboembolism in the USA: now and future. Journal of Thrombosis and Haemostasis
2009; Volume 7, Supplement 2: Abstract OC-WE-018Accessed: 06 December 2011.
5) Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with
edoxaban for thromboprophylaxis after elective total hip replacement. Journal of
Thrombosis and Haemostasis. 2010; 104: 642-649
6) http://www.pmda.go.jp/operations/shonin/...
.
Accessed: 06 December 2011.
7) The Coalition to Prevent VTE. Available at:
http://coalitiontopreventvte.org/index.c... theburden/vid/49CB8F2B-1422-16B3-7884634B147F9253
. Accessed: 06 December 2011.
8) Loue and Sajatovic Encyclopedia of Aging and Public Health 2008, XXIII, 843
p. 10 illus.
9) Lung Disorders 2007 By Peter B. Terry, M.D.
10) Kim and Bartholomew, Cleveland Clinic. Venous Thromboembolism. Available at:
http://www.clevelandclinicmeded.com/medi...
romboembolism/
[http://www.clevelandclinicmeded.com/medi... ]
Accessed: 06 December 2011.
11) Beckman et al CDC Division of Blood Disorders : Public Health Research
Activities in Venous Thromboembolism, Arte-rioscler, Thromb Vasc Biol 2008,
28:394-395.
CONTACT: Contact: Tetsuya Ohira, Daiichi Sankyo Europe GmbH,+49(0)89-78-08-694 (office), +49(0)172-883-9656 (mobile); Daria Munsel,Daiichi Sankyo Europe GmbH, +49 (0)89-78-08-728 (office),+49(0)176-1178-0826 (mobile)
